Aspen Neuroscience Stock

HealthTech

Developer of autologous cell therapies and personalized medicines designed for a broad spectrum of diseases, starting with Parkinson's disease. The company's platform reprograms a patient's own cells into iPSC-derived neuronal precursors, incorporates automation, machine-learning-based quality control, and robotics-driven manufacturing, and places the resulting cells directly into targeted brain regions without immunosuppression, enabling the neurology market to access personalized therapeutic options aimed at restoring dopamine-related function.